RxDoctor Payments Data

Brooks Wiley

Psychiatric/Mental Health · St George, UTNPI 1003267923

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations.

$2,927in general payments, 2019–2025

Across 150 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$572
  • Neurocrine Biosciences, Inc.$270
  • Corium, LLC$224
  • Teva Pharmaceuticals USA, Inc.$190
  • Ironshore Pharmaceuticals Inc.$173
  • Johnson & Johnson$168
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$2,927100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,927 in reported general payments places this provider in the 85th percentile of 393 psychiatric/mental health providers in Utah.

See all psychiatric/mental health providers in Utah

Medicare billing

Part B allowed, 2024
$21,784
Medicare patients
37
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl25$5,729
Buprenorphine Hcl32$2,920
Lisdexamfetamine Dimesylate16$2,728
Bupropion XlBupropion Hcl112$1,617
Lurasidone Hcl27$1,482
Methylphenidate ErMethylphenidate Hcl14$1,149
Clonazepam61$1,116
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine36$1,092
Quetiapine Fumarate80$1,052
Alprazolam72$1,028
Trazodone Hcl79$949
Gabapentin42$907
Tizanidine Hcl13$886
Venlafaxine Hcl ErVenlafaxine Hcl34$645
Fluoxetine Hcl80$642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$18$51499 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 393 psychiatric/mental health providers in Utah.

Other psychiatric/mental health in St George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →